Y Intercept Hong Kong Ltd Makes New $3.66 Million Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Y Intercept Hong Kong Ltd acquired a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 31,781 shares of the company's stock, valued at approximately $3,662,000.

A number of other large investors have also recently bought and sold shares of NBIX. State Street Corp lifted its position in shares of Neurocrine Biosciences by 11.7% in the third quarter. State Street Corp now owns 5,148,293 shares of the company's stock worth $593,186,000 after buying an additional 539,936 shares during the last quarter. 1832 Asset Management L.P. lifted its holdings in Neurocrine Biosciences by 1,370.7% in the 2nd quarter. 1832 Asset Management L.P. now owns 541,200 shares of the company's stock worth $74,507,000 after purchasing an additional 504,400 shares during the last quarter. Los Angeles Capital Management LLC boosted its position in Neurocrine Biosciences by 639.6% during the third quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company's stock worth $48,479,000 after purchasing an additional 363,863 shares during the period. AQR Capital Management LLC boosted its position in Neurocrine Biosciences by 23.0% during the second quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company's stock worth $166,959,000 after purchasing an additional 228,444 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in Neurocrine Biosciences by 9.6% during the second quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company's stock valued at $339,790,000 after purchasing an additional 216,500 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors.

Neurocrine Biosciences Trading Up 0.8 %

NBIX stock traded up $0.98 during trading on Monday, hitting $129.12. The company had a trading volume of 682,433 shares, compared to its average volume of 869,242. The company has a fifty day moving average price of $120.61 and a two-hundred day moving average price of $130.90. Neurocrine Biosciences, Inc. has a fifty-two week low of $110.95 and a fifty-two week high of $157.98. The company has a market cap of $13.07 billion, a P/E ratio of 34.62 and a beta of 0.34.

Analyst Ratings Changes

A number of research firms recently issued reports on NBIX. Raymond James reiterated an "outperform" rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. HC Wainwright reaffirmed a "buy" rating and issued a $190.00 price target on shares of Neurocrine Biosciences in a research report on Friday, November 1st. Royal Bank of Canada cut their price objective on Neurocrine Biosciences from $136.00 to $133.00 and set a "sector perform" rating for the company in a research report on Friday, October 4th. Jefferies Financial Group increased their target price on Neurocrine Biosciences from $177.00 to $189.00 and gave the company a "buy" rating in a research note on Monday, August 19th. Finally, Barclays dropped their price target on Neurocrine Biosciences from $180.00 to $160.00 and set an "overweight" rating on the stock in a research report on Monday, September 9th. Five equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $163.91.

Insider Activity

In related news, insider Jude Onyia sold 2,331 shares of the stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $126.29, for a total transaction of $294,381.99. Following the sale, the insider now directly owns 15,449 shares in the company, valued at $1,951,054.21. This represents a 13.11 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.30% of the stock is owned by corporate insiders.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.